Swiss Biotech OncoEthix Shines In Oversubscribed Series B Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss oncology specialist OncoEthix has raised $19 million in an oversubscribed Series B financing that reflects keen interest in its lead candidate OTX015. The cancer drug belongs to a new class that targets the BET bromodomain protein family.